Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Deffered Revenue (2020 - 2025)

Historic Non-Current Deffered Revenue for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to $10.2 million.

  • Beam Therapeutics' Non-Current Deffered Revenue fell 8242.7% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 8242.7%. This contributed to the annual value of $33.2 million for FY2024, which is 6977.1% down from last year.
  • Per Beam Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $10.2 million for Q3 2025, which was down 8242.7% from $20.3 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Non-Current Deffered Revenue peaked at $262.3 million during Q4 2021, and registered a low of $10.2 million during Q3 2025.
  • Its 5-year average for Non-Current Deffered Revenue is $115.7 million, with a median of $104.7 million in 2023.
  • Per our database at Business Quant, Beam Therapeutics' Non-Current Deffered Revenue skyrocketed by 6647436.55% in 2021 and then plummeted by 8242.7% in 2025.
  • Quarter analysis of 5 years shows Beam Therapeutics' Non-Current Deffered Revenue stood at $262.3 million in 2021, then dropped by 22.92% to $202.2 million in 2022, then crashed by 45.65% to $109.9 million in 2023, then crashed by 69.77% to $33.2 million in 2024, then crashed by 69.41% to $10.2 million in 2025.
  • Its Non-Current Deffered Revenue was $10.2 million in Q3 2025, compared to $20.3 million in Q2 2025 and $49.4 million in Q1 2025.